Health Economics›MSI-H or dMMR›All lines of therapy

All lines of therapy

MSI-H or dMMR · 3 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

FiltersBiomarker

Y-axis

Cost vs Efficacy · 1 point

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Pembrolizumab monotherapy Variant #01	MSI-H	R 286 955	14d	~5.8 mo	~15.5 mo	~13	~R 3 730 419 PFS proxy · indirect	40
Envafolimab monotherapy Variant #01 Partial	MSI-H	—	7d	—	—	—	—	—
Dostarlimab monotherapy Variant #01 Partial	MSI-H	—	42d	—	—	—	—	—

3 of 3 regimens shown